Associations of TA genotypes with features of breast cancer
| Features | Total patients | No. of patients (%) | P | ||
|---|---|---|---|---|---|
| (TA)0 | (TA)0/(TA)9, (TA)9 | ||||
| Age (yr) | |||||
| <45 | 35 | 23 (24.5) | 12 (25.5) | ||
| 45–55 | 36 | 22 (23.4) | 14 (29.8) | 0.65a | |
| >55 | 70 | 49 (52.1) | 21 (44.7) | ||
| Tumor size (cm) | |||||
| <2 | 40 | 26 (28.3) | 14 (30.4) | 0.47b | |
| ≥2 | 98 | 66 (71.7) | 32 (69.6) | ||
| Nodal status | |||||
| Negative | 52 | 31 (34.8) | 21 (45.6) | 0.10b | |
| Positive | 83 | 58 (65.2) | 25 (54.4) | ||
| Gradec | |||||
| I–II | 61 | 44 (65.7) | 17 (53.1) | 0.16b | |
| III | 38 | 23 (34.3) | 15 (46.9) | ||
| Histology | |||||
| Ductal | 98 | 65 (69.2) | 33 (70.2) | ||
| Lobular | 19 | 12 (12.7) | 7 (14.9) | 0.86a | |
| Other | 24 | 17 (18.1) | 7 (14.9) | ||
| Staged | |||||
| I | 42 | 23 (24.7) | 19 (40.4) | ||
| II | 80 | 55 (59.2) | 25 (53.2) | 0.079a | |
| III–IV | 18 | 15 (16.1) | 3 (6.4) | ||
| ER statuse | |||||
| Negative | 46 | 31 (34.4) | 15 (31.9) | 0.46b | |
| Positive | 91 | 59 (65.6) | 32 (68.1) | ||
| PR statuse | |||||
| Negative | 50 | 31 (34.4) | 19 (41.3) | 0.27b | |
| Positive | 86 | 59 (65.6) | 27 (58.7) | ||
| PSA statusf | |||||
| Negative | 119 | 85 (91.4) | 34 (72.3) | 0.004b | |
| Positive | 21 | 8 (8.6) | 13 (27.7) | ||
| Adjuvant treatment | |||||
| None | 41 | 26 (27.7) | 15 (31.9) | ||
| Tamoxifen | 65 | 46 (48.9) | 19 (40.4) | 0.63a | |
| Chemotherapy± tamoxifen | 35 | 22 (23.4) | 13 (27.7) | ||
a χ2 test.
b Fisher’s exact test.
c Bloom-Richardson grading system.
d TNM system.
e Cutoff point: 10 fmol/mg protein.
f Cutoff point: 60 ng/g protein, equal to the 75th percentile of the distribution of PSA concentrations.